Date: 2016-12-05
Type of information: Initiation of development program
phase:
Announcement: initiation of development program
Company: Aduro Biotech (USA - CA) Merck&Co (USA - NJ)
Product: anti-CD27 antibody
Action
mechanism: monoclonal antibody. The CD27 antibody was identified in close collaboration with Prof. Jannie Borst , Ph.D., professor at the University of Amsterdam and division head at the Netherlands Cancer Institute , through Aduro's B-select monoclonal antibody technology. This technology includes a proprietary ultra-selective functional screening process to identify antibodies with unique binding properties against a broad repertoire of targets that can modulate the innate and adaptive arms of the immune system. BioNovion and Merck&Co entered into a worldwide license agreement in 2014 for the development and commercialization of CD27 antibody agonists, and BioNovion received an up-front payment of $15 million . In 2015, Bionovion was acquired by Aduro Biotech and became its subsidiary, Aduro Biotech Europe B.V.
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On December 5, 2016, Aduro Biotech announced today that an anti-CD27 antibody developed by Aduro Biotech Europe and derived from its proprietary B-select technology has been selected to be advanced into clinical development by Merck&Co through a subsidiary. CD27 has been recognized as having a critical role in activating a productive anti-cancer immune response and has demonstrated the potential to be combined with checkpoint inhibitors in pre-clinical studies.
